Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

Queen Mary University of London has launched a new spinout company, Elcella, founded by Dr Madusha Peiris and Dr Rubina Aktar ...

The second largest decline had been the previous year, 2023, meaning that in each of the last two years the country’s most ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

The uninsured rate has been cut in half, but Americans are sicker, and their life expectancy is stagnating. Doing more of the ...